Aadi Bioscience (NASDAQ:AADI) Issues Quarterly Earnings Results

Aadi Bioscience (NASDAQ:AADIGet Rating) announced its earnings results on Thursday. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.02, MarketWatch Earnings reports. During the same quarter last year, the company earned ($0.90) EPS.

Shares of NASDAQ:AADI opened at $14.02 on Friday. Aadi Bioscience has a 1 year low of $11.00 and a 1 year high of $49.80. The firm has a fifty day moving average price of $16.63 and a 200 day moving average price of $20.15.

AADI has been the topic of several recent analyst reports. HC Wainwright cut their target price on shares of Aadi Bioscience from $49.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, April 11th. Zacks Investment Research downgraded shares of Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, January 25th. Finally, Piper Sandler dropped their price target on shares of Aadi Bioscience from $50.00 to $30.00 in a research note on Thursday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Aadi Bioscience currently has a consensus rating of “Buy” and a consensus target price of $40.20.

In related news, insider Neil Desai sold 3,550 shares of the company’s stock in a transaction on Friday, March 18th. The shares were sold at an average price of $20.07, for a total value of $71,248.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.10% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC bought a new stake in shares of Aadi Bioscience in the fourth quarter valued at about $265,000. Renaissance Technologies LLC lifted its stake in shares of Aadi Bioscience by 8.6% in the first quarter. Renaissance Technologies LLC now owns 139,522 shares of the company’s stock valued at $2,368,000 after buying an additional 11,000 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Aadi Bioscience in the fourth quarter worth about $381,000. Susquehanna International Group LLP acquired a new position in Aadi Bioscience in the fourth quarter worth about $530,000. Finally, Geode Capital Management LLC acquired a new position in Aadi Bioscience in the third quarter worth about $825,000. Institutional investors own 62.56% of the company’s stock.

About Aadi Bioscience (Get Rating)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

Featured Articles

Earnings History for Aadi Bioscience (NASDAQ:AADI)

Want More Great Investing Ideas?

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.